/

Mechanism Of Action (MOA) Animation

Medical Animation: PCSK9 LDL Cholesterol Regulation MOA

Created for Biopharmaceutical Client

axs-studio-medical-animation-ldl-recector-mab

Low density lipoproteins binding to LDL receptors (LDLR) on the hepatocyte. A therapeutic antibody binds to proprotein convertase subtilisin-like/Kexin type 9 (PCSK9) to prevent degradation of LDLR. © 2015. All Rights Reserved.

axs-studio-medical-animation-ldl-cholesterol

Low density lipoprotein (LDL) in blood stream surrounded by red blood cells (RBC). © 2015. All Rights Reserved.

axs-studio-medical-animation-ldl-cholesterol-liver-sinosoid

Liver sinusoid containing erythrocytes (red blood cells, RBC) and low density lipoproteins (LDL) surrounded by hepatocytes. © 2015. All Rights Reserved.

The project

This medical animation explores the role of low density lipoprotein cholesterol (LDL-C) in atherosclerotic cardiovascular disease via regulation of LDL-C levels in the liver. By contrasting the LDL-C processing with and without PCSK9, we demonstrate how the latter is a therapeutic target for lowering LDL-C levels in hyperlipidemia. The medical animation goes on to explain the mechanism of action (MOA) of evolucumab, a PCSK9 inhibitor.

Created for
Biopharmaceutical client

More

Mechanism Of Action (MOA) Animation

Title screen from XL309 MOA animation. SL is an emerging strategy for targeting cancer cells. Our client’s lead SL candidate, XL309, inhibits USP1, a deubiquitinase essential for single-strand DNA break repair. Due to compensatory DNA repair mechanisms, XL309 has no effect on healthy cells. However, XL309 is lethal in cancers with homologous recombination (HR)-deficiency that have genetic alterations impairing double-strand DNA break repair. To explain this complex story to multiple audiences, we created a clear, concise MOA animation. Flowchart-like 3D motion graphics make it easy to follow the complex interplay of DNA damage repair mechanisms, while molecular scenes illustrate how the different proteins interact to orchestrate DNA repair.

Synthetic Lethality (SL) Mechanism of Action (MOA) Animation

Exelixis, Inc.

Still image of ZORYVE (roflumilast) cream on a skin cube from a plaque psoriasis drug MOA animation.

Plaque Psoriasis Drug MOA Animation

Arcutis Biotherapeutics

axs-studio-medical-animation-cancer-moa-xb002-01

Medical Animation: Cancer ADC MOA

Exelixis, Inc.

Still image of the CMB complex from a cancer pathway MOD/MOA animation.

Medical Animation: Cancer Small Molecule MOA

Exelixis, Inc.

Still image from the Certepetide MOA animation showing a solid tumor growing.

Scientific Animation: Certepetide MOA

Lisata Therapeutics

Title slide from zanzalintinib (XL092) mechanism of action (MOA) animation. XL092 is a small-molecule inhibitor of multiple receptor tyrosine kinases (RTKs) that are involved in cancer growth and immune regulation. Animation is divided into chapters. A web-based interactive version of the video was developed for use at congresses. Animation launched at AACR 2022.

Oncology MOD and MOA Animation

Exelixis, Inc

axs-studio-medical-animation-melanoma-BRAF-MOA-01b

Medical Animation: BRAF Inhibitor for Melanoma

Biopharmaceutical client

axs-studio-medical-animation-hodgkin-lymphoma-immunotherapy-MOA-Reed-Sternberg-cell

Hodgkin Lymphoma Immunotherapy Animation

Biopharmaceutical client

axs-studio-medical-animation-antibody-drug-conjugate-endocytosis

Medical Animation: Immuno-Oncology ADC MOA

Biopharmaceutical client

axs-studio-medical-animation-oncology-immunotherapy-trojan

Medical Animation: Cancer Immunotherapy MOA

Biopharmaceutical client

axs-studio-medical-animation-osteoporosis-drug-MOA-01

Osteoporosis Animation: Sclerostin Inhibitor MOA

Biopharmaceutical client

axs-studio-medical-animation-ldl-recector-mab

Medical Animation: PCSK9 LDL Cholesterol Regulation MOA

Biopharmaceutical Client